Related references
Note: Only part of the references are listed.Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer
T. Telkhade et al.
CLINICAL ONCOLOGY (2021)
Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer
Keisuke Tsuchida et al.
CANCER MEDICINE (2020)
Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer
Itsuto Hamano et al.
WORLD JOURNAL OF UROLOGY (2019)
Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis
Dominic H. Moon et al.
CLINICAL GENITOURINARY CANCER (2018)
Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer
Giorgio Gandaglia et al.
EUROPEAN UROLOGY (2017)
Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy
Moses Arunsingh et al.
MEDICAL DOSIMETRY (2017)
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study
Pascal Pommier et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer Data From Patients in the Control Arm of the STAMPEDE Trial
Nicholas D. James et al.
JAMA ONCOLOGY (2016)
What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
Nicholas G. Zaorsky et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy
Jeremy Yuen Chun Teoh et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
The Impact of Definitive Local Therapy for Lymph Node-Positive Prostate Cancer: A Population-Based Study
Chad G. Rusthoven et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol
Yoshiki Norihisa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2012)
Toxicity and outcome of pelvic IMRT for node-positive prostate cancer
A. -C. Mueller et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2012)
Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer
Jutta Engel et al.
EUROPEAN UROLOGY (2010)
Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy? A Systematic Review
Paul C. M. S. Verhagen et al.
EUROPEAN UROLOGY (2010)
Stage IV Prostate Cancer: Survival Differences in Clinical T4, Nodal and Metastatic Disease
Wayland Hsiao et al.
JOURNAL OF UROLOGY (2010)
Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade
Norihito Soga et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2008)
Feasibility of IMRT to cover pelvic nodes while escalating the dose to the prostate gland: Dosimetric data on 35 consecutive patients
John E. Bayouth et al.
MEDICAL DOSIMETRY (2008)
Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01
Pascal Pommier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Current status of lymph node-positive prostate cancer - Incidence and predictors of outcome
Gregory P. Swanson et al.
CANCER (2006)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer
XA Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation therapy oncology group 9413
M Roach et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
